The FDA has released draft guidance that aims to clear up how drug developers can use alternative testing – but that doesn’t mean animal testing in the US is over.

The boss of Yorkshire-based lateral flow test developer Abingdon Health has said the company is still benefiting after the pandemic turned a once rarely discussed product into a household name.

Joe Reader is running the London Marathon to raise awareness for Coeliac UK and help fund crucial research which could lead to more diagnoses.

After a strong start to the year, the value of biotech financings has tailed off a little, but March has seen a clutch of $50 ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...

Eli Lilly and Eisai's battle to secure NHS reimbursement for their Alzheimer's disease therapies is dragging on, with guidance blocking use of the drug set for another review. After a successful ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

Researchers are seeking pregnant patients for the clinical trial of a drug designed to decrease the risk of fetal anemia in patients with hemolytic disease of the fetus and newborn (HDFN).

Global Immigration Partners, a leading immigration advisory firm, has released new insights to help international investors ...

CODX (NASDAQ:CODX) is making a strategic push to scale its global diagnostics platform, announcing a major expansion of ...

Healthtech and edtech are two of the fastest growing sectors, with the healthtech market size to reach $3.1 billion by 2033, ...